Author
@OzmosiHealth OzmosiHealth
Real-time biotech catalyst and regulatory event feed across hundreds of clinical-stage names
Publishes a structured, link-backed stream of biotech/pharma
trader score
·
hit rate
·
mean α
·
signals 14d
195
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved +2.1% since posting (mean over 54 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-07-02 | RVMD | @OzmosiHealth | +0.20 | Revolution Medicines presents Phase 1/2 clinical data at ESMO GI Cancers Congress. | — | tweet ↗ |
| 2026-07-02 | RHHBY | @OzmosiHealth | +0.45 | Roche divarasib shows superiority in head-to-head phase III trial. | — | tweet ↗ |
| 2026-07-02 | RHHBY | @OzmosiHealth | +0.45 | Roche divarasib shows superiority in head-to-head phase III trial. | — | tweet ↗ |
| 2026-07-02 | RHHBY | @OzmosiHealth | +0.45 | Genentech divarasib shows superiority in Phase III NSCLC trial. | — | tweet ↗ |
| 2026-07-02 | BBIO | @OzmosiHealth | +0.35 | Acoramidis associated with early and sustained kidney-protective effects. | — | tweet ↗ |
| 2026-07-02 | RHHBY | @OzmosiHealth | +0.45 | Genentech divarasib shows superiority in Phase III NSCLC trial. | — | tweet ↗ |
| 2026-07-02 | NKGN | @OzmosiHealth | +0.15 | NKGen to present at BIOCHINA forum on troculeucel potential. | · | tweet ↗ |
| 2026-07-02 | LEUKINE | @OzmosiHealth | +0.20 | Partner Therapeutics announces JCO publication of eNRGy trial results. | · | tweet ↗ |
| 2026-07-02 | ARCT | @OzmosiHealth | +0.40 | Arcturus announces strategic collaboration with Thermo Fisher for ARCT-032. | · | tweet ↗ |
| 2026-07-01 | NBIX | @OzmosiHealth | +0.25 | Neurocrine initiates Phase 2 study of crinecerfont in pediatric patients. | +3.9% | tweet ↗ |
| 2026-07-01 | VTGN | @OzmosiHealth | +0.05 | VistaGen presented Phase 3 social phobia results on 2026-06-30. | · | tweet ↗ |
| 2026-07-01 | PTIX | @OzmosiHealth | +0.05 | Protagenic presented Phase 0 treatment-resistant depression results on 2026-06-30. | · | tweet ↗ |
| 2026-07-01 | KTTA | @OzmosiHealth | +0.05 | Pasithea presented Phase 1 solid tumor results on 2026-06-30. | · | tweet ↗ |
| 2026-07-01 | MBRX | @OzmosiHealth | +0.05 | Moleculin presented Phase 2 AML results on 2026-06-30. | · | tweet ↗ |
| 2026-07-01 | CTNM | @OzmosiHealth | +0.05 | Contineum presented Phase 0 MS/IPF results on 2026-06-29. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.